Global Sepsis Diagnostics Market Size (2024 - 2029)

The sepsis diagnostics market is projected to experience growth due to several key factors, including the increasing incidence of sepsis, particularly among COVID-19 patients, and the rising burden of hospital-acquired infections. The market's expansion is further supported by the growing number of pneumonia cases, an increase in sepsis procedures, and enhanced funding for sepsis-related research activities. These elements are expected to create new opportunities for innovative diagnostic solutions, driving the overall market size during the forecast period.

Home Market Analysis Healthcare Research Medical Devices Research Diagnostic Devices Research Clinical Diagnostic Devices Research Clinical Diagnostic Laboratory Equipment Research Disease Specific Diagnostic Devices Research Infectious Disease Testing Research Sepsis Treatment Industry Market Size

Market Size of Global Sepsis Diagnostics Industry

Sepsis Diagnostics Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 0.74 Billion
Market Size (2029) USD 1.02 Billion
CAGR (2024 - 2029) 6.58 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Sepsis Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Sepsis Diagnosis Market Analysis

The Global Sepsis Diagnostics Market size is estimated at USD 0.74 billion in 2024, and is expected to reach USD 1.02 billion by 2029, growing at a CAGR of 6.58% during the forecast period (2024-2029).

Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the market studied. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. Furthermore, according to a study published by PLOS in August 2021, 'Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,' COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel diagnosis in the market studied.

The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in the United States. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat and evaluate maternal sepsis.

Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.

Sepsis Diagnosis Industry Segmentation

As per the scope of this report, sepsis diagnostics is the study of diagnosis of sepsis, which is a serious and life-threatening clinical condition that generally results from primary bacterial infection or, less frequently, from a fungal and/or viral infection. The sepsis diagnostics market is segmented by technology (molecular diagnostics, microbiology, immunoassay, and other technologies), product (instruments, assays and reagents, other products), diagnostic method (conventional diagnostics, automated diagnostics), pathogen (bacterial sepsis, fungal sepsis, other pathogens), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Technology
Molecular Diagnostics
Microbiology
Immunoassay
Other Technologies
By Product
Instruments
Assays and Reagents
Other Products
By Diagnostic Method
Conventional Diagnostics
Automated Diagnostics
By Pathogen
Bacterial Sepsis
Fungal Sepsis
Other Pathogens
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Sepsis Diagnostics Market Size Summary

The sepsis diagnostics market is poised for significant growth, driven by the increasing incidence of sepsis, particularly among COVID-19 patients, and the rising burden of hospital-acquired infections. The market is characterized by the need for rapid and accurate profiling of infection-causing pathogens, which is crucial for selecting appropriate antibiotic therapy. Molecular diagnostics have emerged as a promising approach due to their feasibility and accuracy, although high costs compared to conventional procedures have been a barrier to market expansion. The development of point-of-care molecular diagnostics and innovative tests, such as Immunexpress's rapid SeptiCyte, highlights the industry's focus on improving early diagnosis and patient management. Additionally, research initiatives and funding for sepsis-related studies are expected to further propel market growth.

North America holds a significant share of the sepsis diagnostics market, supported by a high incidence rate of the disease and substantial investments in research and development. The market is moderately consolidated, with key players like Abbott, Becton, Dickinson and Company, and bioMérieux SA driving innovation and product launches. Collaborations and partnerships, such as Cytovale Inc.'s expansion with BARDA, underscore the ongoing efforts to enhance sepsis diagnosis, particularly in patients with respiratory infections. Regulatory approvals, like Immunoexpress's FDA approval for SeptiCyte RAPID, and strategic agreements, such as Prenosis Inc.'s partnership with Roche Diagnostics, are expected to contribute to the market's growth trajectory.

Explore More

Global Sepsis Diagnostics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Burden of Sepsis

      2. 1.2.2 Growing Incidence of Hospital-acquired Infections

      3. 1.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Automated Diagnostic Instruments

      2. 1.3.2 Lack of Well-established Reimbursement Policies for Sepsis

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Technology

      1. 2.1.1 Molecular Diagnostics

      2. 2.1.2 Microbiology

      3. 2.1.3 Immunoassay

      4. 2.1.4 Other Technologies

    2. 2.2 By Product

      1. 2.2.1 Instruments

      2. 2.2.2 Assays and Reagents

      3. 2.2.3 Other Products

    3. 2.3 By Diagnostic Method

      1. 2.3.1 Conventional Diagnostics

      2. 2.3.2 Automated Diagnostics

    4. 2.4 By Pathogen

      1. 2.4.1 Bacterial Sepsis

      2. 2.4.2 Fungal Sepsis

      3. 2.4.3 Other Pathogens

    5. 2.5 By Geography

      1. 2.5.1 North America

        1. 2.5.1.1 United States

        2. 2.5.1.2 Canada

        3. 2.5.1.3 Mexico

      2. 2.5.2 Europe

        1. 2.5.2.1 Germany

        2. 2.5.2.2 United Kingdom

        3. 2.5.2.3 France

        4. 2.5.2.4 Italy

        5. 2.5.2.5 Spain

        6. 2.5.2.6 Rest of Europe

      3. 2.5.3 Asia-Pacific

        1. 2.5.3.1 China

        2. 2.5.3.2 Japan

        3. 2.5.3.3 India

        4. 2.5.3.4 Australia

        5. 2.5.3.5 South Korea

        6. 2.5.3.6 Rest of Asia-Pacific

      4. 2.5.4 Middle-East and Africa

        1. 2.5.4.1 GCC

        2. 2.5.4.2 South Africa

        3. 2.5.4.3 Rest of Middle-East and Africa

      5. 2.5.5 South America

        1. 2.5.5.1 Brazil

        2. 2.5.5.2 Argentina

        3. 2.5.5.3 Rest of South America

Global Sepsis Diagnostics Market Size FAQs

The Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion in 2024 and grow at a CAGR of 6.58% to reach USD 1.02 billion by 2029.

In 2024, the Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion.

Sepsis Diagnostics Market Report Snapshots

Sepsis Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)